Generic Weight Loss Drug Prices Set to Plummet as Patent Expires

The patent expiry of Semaglutide in March 2026 is a game-changer because it will allow generic versions to enter the market, drastically reducing its cost by up to 60%. This makes an effective weight-loss drug, currently priced at Rs 10,000-12,000 per month, affordable for a much wider population (projected Rs 4,000-5,000 per month). India's patent law, specifically the Indian Patent Act, 1970, is designed to balance innovator rights with public access, ensuring that after a patent expires, generic manufacturers can produce and sell the drug, thereby increasing competition and affordability.

The Indian Patent Act, 1970, primarily grants exclusive rights to patentees for a certain period (usually 20 years for pharmaceutical products). Once this period expires, as with Semaglutide in March 2026, the invention enters the public domain, allowing any manufacturer to produce generic versions. While the Act also includes provisions like 'compulsory licensing' (Section 84) to ensure public access even before patent expiry under specific conditions (like national emergency or unaffordability), the current scenario with Semaglutide is a straightforward patent expiry.

The drastic price reduction of Semaglutide will significantly support India's public health goals by making an effective weight-loss treatment accessible to a much larger population. This aligns with the National Health Policy 2017's emphasis on affordable and accessible healthcare for all.

• •Tackling Obesity: Obesity is a growing concern in India, contributing to various non-communicable diseases (NCDs) like diabetes and heart disease. Cheaper Semaglutide can help manage obesity more effectively.
• •Reducing NCD Burden: By addressing obesity, the drug can indirectly help reduce the burden of NCDs, improving overall public health outcomes.
• •Promoting Affordability: It reinforces the government's strategy of promoting generic medicines, as seen in initiatives like the Pradhan Mantri Jan Aushadhi Pariyojana, ensuring quality drugs at lower prices.

The fundamental difference lies in their origin and pricing, not necessarily their active ingredient or efficacy.

• •Branded Drug: This is the original drug developed and marketed by a pharmaceutical company after extensive research and development. It holds a patent, granting exclusive manufacturing and selling rights for a period. This exclusivity allows the company to set high prices to recoup R&D costs and make a profit. Examples are Ozempic and Wegovy (both containing Semaglutide).
• •Generic Drug: This is a copy of a branded drug, manufactured after the original drug's patent expires. Generic drugs contain the same active ingredient, strength, dosage form, and route of administration as the branded version. They are bioequivalent, meaning they work the same way in the body. Since generic manufacturers don't bear R&D costs, they can sell the drug at significantly lower prices.
• •Crucial for Patients: This distinction is crucial because generic drugs offer the same therapeutic benefits at a fraction of the cost, making essential medicines accessible and affordable to a much wider patient population, especially in developing countries like India.

While price reduction is a major step, several challenges remain for widespread and equitable access to generic Semaglutide in India.

• •Awareness and Diagnosis: Many individuals, especially in rural areas, may not be aware of obesity as a treatable condition or have access to proper diagnosis and medical consultation for such drugs.
• •Healthcare Infrastructure: Limited healthcare infrastructure, including fewer doctors, clinics, and pharmacies in remote areas, can hinder availability and proper prescription.
• •Cold Chain Management: Semaglutide is an injectable drug, often requiring specific storage conditions (cold chain). Maintaining this infrastructure, especially in areas with unreliable electricity, can be a challenge.
• •Doctor's Prescription: The drug requires a doctor's prescription, and access to qualified medical professionals who can correctly diagnose and prescribe it is crucial.
• •Long-term Adherence: Weight loss treatment often requires long-term adherence. Ensuring patients continue treatment, even with reduced costs, requires ongoing medical support and education.

March 2026 is significant because it marks the patent expiry date for Semaglutide, which will open the market for generic versions and drastically reduce its price.

• •60%: The expected percentage reduction in the drug's cost.
• •Rs 10,000 to Rs 12,000: The current monthly cost range of branded Semaglutide (Ozempic/Wegovy) in India.
• •Rs 4,000 to Rs 5,000: The projected monthly cost range for generic alternatives.